Avanafil, a new rapid-onset phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction

Bibliography

• Lue TF, Giuliano F, Montorsi F, Summary of the recommendations on sexual dysfunctions in men. J Sex Med 2004;1:6-23
   PubMed Web of Science ®Google Scholar
• Guest JF, Das Gupta R. Health-related quality of life in a UK-based population of men with erectile dysfunction. Pharmacoeconomics 2002;20:109-17
   PubMed Web of Science ®Google Scholar
• Mirone V, Fusco F, Rossi A, Tadalafil and vardenafil vs sildenafil: a review of patient-preference studies. BJU Int 2009;103:1212-17
   PubMed Web of Science ®Google Scholar
• Costa P, Grivel T, Giuliano F, Erectile dysfunction: a sentinel symptom? Prog Urol 2005;15:203-7
   PubMed Web of Science ®Google Scholar
• Wagner G, Fugl-Meyer KS, Fugl-Meyer AR. Impact of erectile dysfunction on quality of life: patient and partner perspectives. Int J Impot Res 2000;12(Suppl 4):S144-6
   PubMed Web of Science ®Google Scholar
• Feldman HA, Goldstein I, Hatzichristou DG, Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994;151:54-61
   PubMed Web of Science ®Google Scholar
• Haczynski J, Lew-Starowicz Z, Darewicz B, The prevalence of erectile dysfunction in men visiting outpatient clinics. Int J Impot Res 2006;18:359-63
   PubMed Web of Science ®Google Scholar
• Ayta IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int 1999;84:50-6
   PubMed Web of Science ®Google Scholar
• McKinlay JB. The worldwide prevalence and epidemiology of erectile dysfunction. Int J Impot Res 2000;12(Suppl 4):S6-11
   PubMed Web of Science ®Google Scholar
• Ponholzer A, Temml C, Mock K, Prevalence and risk factors for erectile dysfunction in 2869 men using a validated questionnaire. Eur Urol 2005;47:80-5; discussion 85-86
   PubMed Web of Science ®Google Scholar
• Rosen RC, Wing R, Schneider S, Epidemiology of erectile dysfunction: the role of medical comorbidities and lifestyle factors. Urol Clin North Am 2005;32:403-17, v
   PubMed Web of Science ®Google Scholar
• Kapur V, Chien CV, Fuess JE, The relationship between erectile dysfunction and cardiovascular disease. Part II: the role of PDE-5 inhibition in sexual dysfunction and cardiovascular disease. Rev Cardiovasc Med 2008;9:187-95
   PubMed Web of Science ®Google Scholar
• Miner MM. Erectile dysfunction and the “window of curability”: a harbinger of cardiovascular events. Mayo Clin Proc 2009;84:102-4
   PubMed Web of Science ®Google Scholar
• Shabsigh R, Shah M, Sand M. Erectile dysfunction and men's health: developing a comorbidity risk calculator. J Sex Med 2008;5:1237-43
   PubMed Web of Science ®Google Scholar
• Lue TF. Erectile dysfunction. N Engl J Med 2000;342:1802-13
   PubMed Web of Science ®Google Scholar
• Cour F, Fabbro-Peray P, Cuzin B, Recommendations to general practice doctors for first line management of erectile dysfunction. Prog Urol 2005;15:1011-20
   PubMed Web of Science ®Google Scholar
• Dean J, Hackett GI, Gentile V, Psychosocial outcomes and drug attributes affecting treatment choice in men receiving sildenafil citrate and tadalafil for the treatment of erectile dysfunction: results of a multicenter, randomized, open-label, crossover study. J Sex Med 2006;3:650-61
   PubMed Web of Science ®Google Scholar
• Ignarro LJ, Bush PA, Buga GM, Nitric oxide and cyclic GMP formation upon electrical field stimulation cause relaxation of corpus cavernosum smooth muscle. Biochem Biophys Res Commun 1990;170:843-50
   PubMed Web of Science ®Google Scholar
• Rajfer J, Aronson WJ, Bush PA, Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N Engl J Med 1992;326:90-4
   PubMed Web of Science ®Google Scholar
• Burnett AL, Nelson RJ, Calvin DC, Nitric oxide-dependent penile erection in mice lacking neuronal nitric oxide synthase. Mol Med 1996;2:288-96
   PubMed Web of Science ®Google Scholar
• Burnett AL. Role of nitric oxide in the physiology of erection. Biol Reprod 1995;52:485-9
   PubMed Web of Science ®Google Scholar
• Andersson KE. Pharmacology of penile erection. Pharmacol Rev 2001;53:417-50
   PubMed Web of Science ®Google Scholar
• Andersson KE, Stief CG. Neurotransmission and the contraction and relaxation of penile erectile tissues. World J Urol 1997;15:14-20
   PubMed Web of Science ®Google Scholar
• Kim NN. Phosphodiesterase type 5 inhibitors: a biochemical and clinical correlation survey. Int J Impot Res 2003;15(Suppl 5):S13-19
   PubMed Web of Science ®Google Scholar
• Wespes E, Amar E, Hatzichristou D, EAU Guidelines on erectile dysfunction: an update. Eur Urol 2006;49:806-15
   PubMed Web of Science ®Google Scholar
• Montague DK, Jarow JP, Broderick GA, Chapter 1: the management of erectile dysfunction: an AUA update. J Urol 2005;174:230-9
   PubMed Web of Science ®Google Scholar
• Eardley I, Donatucci C, Corbin J, Pharmacotherapy for erectile dysfunction. J Sex Med 2010;7:524-40
   PubMed Web of Science ®Google Scholar
• Gingell C, Sultana SR, Wulff MB, Duration of action of sildenafil citrate in men with erectile dysfunction. J Sex Med 2004;1:179-84
   PubMed Web of Science ®Google Scholar
• Gupta M, Kovar A, Meibohm B. The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction. J Clin Pharmacol 2005;45:987-1003
   PubMed Web of Science ®Google Scholar
• Hatzimouratidis K, Amar E, Eardley I, Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol 2010;57:804-14
   PubMed Web of Science ®Google Scholar
• Seftel AD. Phosphodiesterase type 5 inhibitors: molecular pharmacology and interactions with other phosphodiesterases. Curr Pharm Des 2005;11:4047-58
   PubMed Web of Science ®Google Scholar
• Carrier S. Pharmacology of phosphodiesterase 5 inhibitors. Can J Urol 2003;10(Suppl 1):12-16
   PubMedGoogle Scholar
• Corbin JD, Francis SH. Pharmacology of phosphodiesterase-5 inhibitors. Int J Clin Pract 2002;56:453-9
   PubMed Web of Science ®Google Scholar
• Hatzimouratidis K, Hatzichristou DG. A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient? Drugs 2005;65:1621-50
   PubMed Web of Science ®Google Scholar
• Hellstrom WJ, Overstreet JW, Yu A, Tadalafil has no detrimental effect on human spermatogenesis or reproductive hormones. J Urol 2003;170:887-91
   PubMed Web of Science ®Google Scholar
• Vlachopoulos C, Ioakeimidis N, Rokkas K, Cardiovascular effects of phosphodiesterase type 5 inhibitors. J Sex Med 2009;6:658-74
   PubMed Web of Science ®Google Scholar
• Kloner RA. Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactions. Am J Cardiol 2005;96:42M-6M
   Google Scholar
• Kendirci M, Tanriverdi O, Trost L, Management of sildenafil treatment failures. Curr Opin Urol 2006;16:449-59
   PubMed Web of Science ®Google Scholar
• Hatzimouratidis K, Hatzichristou DG. Looking to the future for erectile dysfunction therapies. Drugs 2008;68:231-50
   PubMed Web of Science ®Google Scholar
• Positive Results From Phase 3 Study of Avanafil in Erectile Dysfunction Presented at AUA Annual Meeting, VIVUS, Inc., press releases, 1 June 2010, Available from: http://ir.vivus.com/releasedetail.cfm?ReleaseID=475141 [Last accessed 28 August 2010]
   Google Scholar
• TA-1790. Investigator Brochure. Edition 6. VIVUS, Inc., Minneapolis; 2008. p. 14
   Google Scholar
• TA-1790. Investigator Brochure. Edition 6. VIVUS, Inc., Minneapolis; 2008. p. 15
   Google Scholar
• Laties A, Sharlip I. Ocular safety in patients using sildenafil citrate therapy for erectile dysfunction. J Sex Med 2006;3:12-27
   PubMed Web of Science ®Google Scholar
• Zhang J, Kuvelkar R, Wu P, Differential inhibitor sensitivity between human recombinant and native photoreceptor cGMP-phosphodiesterases (PDE6s). Biochem Pharmacol 2004;68:867-773
   PubMed Web of Science ®Google Scholar
• Laties A, Zrenner E. Viagra (sildenafil citrate) and ophthalmology. Prog Retin Eye Res 2002;21:485-506
   PubMed Web of Science ®Google Scholar
• TA-1790. Investigator Brochure. Edition 6. VIVUS, Inc., Minneapolis; 2008. p. 16-17
   Google Scholar
• TA-1790. Investigator Brochure. Edition 6. VIVUS, Inc., Minneapolis: 2008. p. 15-16
   Google Scholar
• Jackson G, Montorsi P, Cheitlin MD. Cardiovascular safety of sildenafil citrate (Viagra): an updated perspective. Urology 2006;68:47-60
   PubMed Web of Science ®Google Scholar
• Padma-nathan H, Eardley I, Kloner RA, A 4-year update on the safety of sildenafil citrate (Viagra). Urology 2002;60:67-90
   PubMed Web of Science ®Google Scholar
• TA-1790. Investigator Brochure. Edition 6. VIVUS, Inc., Minneapolis; 2008. p. 17
   Google Scholar
• TA-1790. Investigator Brochure. Edition 6. VIVUS, Inc., Minneapolis; 2008. p. 17-18
   Google Scholar
• TA-1790. Investigator Brochure. Edition 6. VIVUS, Inc., Minneapolis; 2008. p. 18-19
   Google Scholar
• TA-1790. Investigator Brochure. Edition 6. VIVUS, Inc., Minneapolis; 2008. p. 20-6
   Google Scholar
• A-1790. Investigator Brochure. Edition 6. VIVUS, Inc., Minneapolis; 2008. p. 45-6
   Google Scholar
• Peterson C, Swearingen D. Pharacokinetics of avanafil, a new PDE5 inhibitor being developed for treating erectile dysfunction. J Sex Med 2006;3(suppl 3):253-4
   PubMed Web of Science ®Google Scholar
• Lewis RW, Hellstrom WJG, Gittelman M, Rigiscan evaluation of TA-1790, a novel PDE5 inhibitor for the treatment of men with erectile dysfunction [abstract 1196]. J Urol 2004;171(Suppl):316
   PubMedGoogle Scholar
• Results announced for TA-1790 Phase II head-to-head study with Viagra. VIVUS, Inc., press releases March 4, 2004. Available from: http://www.obgyn.net/newsheadlines/womens_health-Erectile_Dysfunction-20040304-63.asp. [Last accessed 28 August 2010]
   Google Scholar
• Nehra A, Swearingen D, Dietrich J, Peterson C. Haemodynamic effects of co-administration of avanafil and glyceryl trinitrate. Eur Urol Suppl 2006;5(2):138
   Web of Science ®Google Scholar
• Kaufman J, Dietrich J. Safety and efficacy of avanafil, a new PDE5 inhibitor for treating erectile dysfunction. Eur Urol Suppl 2006;5(2):138
   Web of Science ®Google Scholar
• Goldstein I, Bowden C, DiDonato K, “Investigating avanafil in the treatment of erectile dysfunction: results of a Phase III, multicenter, randomized, double-blind, placebo controlled clinical trial”. AUA Late-Breaking Science Forum 2010, San Francisco, CA, USA
   Google Scholar
• Vivus announces positive results from phase 3 study of avanafil in diabetics with erectile dysfunction. VIVUS, Inc., PRESS RELEASES June 7, 2010. Available from: http://ir.vivus.com/releasedetail.cfm?ReleaseID=476930. [Last accessed 28 August 2010]
   Google Scholar
• Conti M, Beavo J. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem 2007;76:481-511
   PubMed Web of Science ®Google Scholar
• Cote RH. Characteristics of photoreceptor PDE (PDE6): similarities and differences to PDE5. Int J Impot Res 2004;16(Suppl 1):S28-33
   PubMed Web of Science ®Google Scholar
• Laties AM. Vision disorders and phosphodiesterase type 5 inhibitors: a review of the evidence to date. Drug Saf 2009;32:1-18
   PubMed Web of Science ®Google Scholar
• Kostis JB, Jackson G, Rosen R, Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). Am J Cardiol 2005;96:313-21
   PubMed Web of Science ®Google Scholar
• Braunwald E, Antman EM, Beasley JW, ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction – summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 2002;40:1366-74
   PubMed Web of Science ®Google Scholar
• Schermuly RT, Kreisselmeier KP, Ghofrani HA, Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. Am J Respir Crit Care Med 2004;169:39-45
   PubMed Web of Science ®Google Scholar
• Ghofrani HA, Voswinckel R, Reichenberger F, Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J Am Coll Cardiol 2004;44:1488-96
   PubMed Web of Science ®Google Scholar
• Montani D, Chaumais MC, Savale L, Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension. Adv Ther 2009;26:813-25
   PubMed Web of Science ®Google Scholar
• Malavige LS, Jayaratne SD, Kathriarachchi ST, Erectile dysfunction among men with diabetes is strongly associated with premature ejaculation and reduced libido. J Sex Med 2008;5:2125-34
   PubMed Web of Science ®Google Scholar
• El-Sakka AI, Tayeb KA. Erectile dysfunction risk factors in noninsulin dependent diabetic Saudi patients. J Urol 2003;169:1043-7
   PubMed Web of Science ®Google Scholar
• Sasaki H, Yamasaki H, Ogawa K, Prevalence and risk factors for erectile dysfunction in Japanese diabetics. Diabetes Res Clin Pract 2005;70:81-9
   PubMed Web of Science ®Google Scholar
• Malavige LS, Levy JC. Erectile dysfunction in diabetes mellitus. J Sex Med 2009;6:1232-47
   PubMed Web of Science ®Google Scholar
• Rendell MS, Rajfer J, Wicker PA, Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group. JAMA 1999;281:421-6
   PubMed Web of Science ®Google Scholar
• Goldstein I, Young JM, Fischer J, Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care 2003;26:777-83
   PubMed Web of Science ®Google Scholar
• Saenz de Tejada I, Anglin G, Knight JR, Effects of tadalafil on erectile dysfunction in men with diabetes. Diabetes Care 2002;25:2159-64
   PubMed Web of Science ®Google Scholar